石药集团则将获得12亿美元的预付款、最高35亿美元的研发里程碑付款、138亿美元的销售里程碑付 款，以及最高达双位数比例的销售提成。此次合作也创下GLP-1赛道海外BD交易的新纪录。 据介绍，此次合作标的长效技术可实现多肽药物的缓释，使给药间隔达到每月一次或更长。AI技术台 可以针对药物靶点快速设计及筛选候选分子，在药效、选择性与信号偏向性等维度进行系统优化。 但资本市场反应却一反常态。截至发稿，石药集团港股股价跌超11%。 研发实力的稳步提升，也推动石药集团创新管线加速兑现。财报显示，截至2025年9月底，其已落地4笔 BD交易，累计实现授权收入15.40亿元。 值得一提的是，阿斯利康与石药集团已达成多次合作。早在2024年10月，双方就签订独家许可协议，推 进Lp(a)干扰剂YS2302018的开发。后又在去年6月宣布共同开发新型口服小分子候选药物，潜在交易总 金额达53.3亿美元。 1月30日，石药集团在港交所发布公告，宣布与阿斯利康达成协议，将利用其专有的缓释给药技术平台 及多肽药物AI发现平台，开发创新长效多肽药物，合作潜在交易价值高达185亿美元。 而石药集团之所以能持续获得阿斯利康青睐，离不开其 ...

1月30日，石药集团宣布与阿斯利康签订战略研发合作与授权协议，以利用石药集团专有的缓释给药技术 平台及多肽药物AI发现平台开发创新长效多肽药物。 石药集团的长效技术可实现多肽药物的缓释，使给药间隔达到每月一次或更长。基于此平台开发的产品 为即用型，使用简便，支持患者自行给药，能有效提升长期用药人群的治疗依从性。同时，石药集团的 多肽药物AI发现平台可以针对药物靶点快速设计及筛选候选分子，并可在药效、选择性与信号偏向性等 维度进行系统优化。 根据该协议的条款，石药集团将与阿斯利康在创新多肽分子的发现和长效递送产品的开发方面开展全面 战略合作。除持续推进现有临床前长效多肽管线之外，石药集团亦将为阿斯利康发现和开发其他创新长 效多肽产品。 除中国内地、香港特别行政区、澳门特别行政区及台湾地区外，阿斯利康将获得石药集团每月一次注射 用体重管理产品组合的全球独家权利，包括一个临床准备就绪的项目SYH2082（长效GLP1R/GIPR激动 剂，正推进至I期临床），以及三个处于临床前阶段、具备不同作用机制的研发项目，旨在为肥胖及体重 问题相关人群提供更持久的治疗获益，双方还将依托该等平台就另外四个新增项目开展合作。 按照该 ...

Core Viewpoint - The strategic collaboration between CSPC Pharmaceutical Group and AstraZeneca aims to develop innovative long-acting peptide drugs, leveraging CSPC's proprietary drug delivery technology and AI discovery platform, with a potential total value of up to $18.5 billion [2][5][6]. Group 1: Collaboration Details - CSPC has signed a strategic R&D collaboration and licensing agreement with AstraZeneca, which includes a $1.2 billion upfront payment and potential milestone payments of up to $3.5 billion for R&D and $13.8 billion for sales [2][5]. - AstraZeneca will gain exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize a weight management product portfolio, including the clinical-ready project SYH2082 [5][6]. - The collaboration will also focus on developing four additional projects based on CSPC's technology platforms [5]. Group 2: Market Potential - The global obesity issue is projected to escalate, with over 2.9 billion adults expected to be classified as having a high BMI by 2030, driving demand for GLP-1 receptor agonists [6][7]. - The GLP-1RA market is anticipated to reach a valuation of $100 billion by 2030, attracting significant interest from pharmaceutical companies [7][8]. - Existing GLP-1 drugs have shown substantial revenue growth, with Eli Lilly's drug generating $24.837 billion in revenue in the first three quarters of 2025, accounting for 54% of its total revenue [6][7]. Group 3: Competitive Landscape - The GLP-1 market is transitioning from an early "blue ocean" phase to a competitive landscape dominated by major players like Novo Nordisk and Eli Lilly, with ongoing opportunities for differentiation and innovation [7][8]. - Current trends in GLP-1 drug development are focusing on multi-target approaches, longer efficacy, and more convenient administration methods, with oral formulations becoming a key competitive focus [7][8]. Group 4: Financial Context - CSPC's recent collaborations are part of a broader trend in the biopharmaceutical sector, where partnerships are increasingly seen as a means to enhance cash flow and support ongoing R&D efforts [11][12]. - Despite recent collaborations, CSPC has faced financial pressures, with a reported revenue decline of 12.32% year-on-year for the first three quarters of 2025 [12].

Group 1 - The stock price of CSPC Pharmaceutical Group fell by 12% to HKD 9.41, leading the decline in the Hang Seng Index [2]

Core Viewpoint - The stock of CSPC Pharmaceutical Group (1093.HK) experienced a significant decline of 12.54%, closing at HKD 9.35, with trading volume exceeding HKD 3.8 billion following the announcement of a strategic research and development collaboration with AstraZeneca [1] Group 1: Company Developments - CSPC Pharmaceutical Group has signed a strategic research and development collaboration and licensing agreement with AstraZeneca to utilize its proprietary sustained-release drug delivery technology platform and AI discovery platform for innovative long-acting peptide drugs [1] - The agreement entails comprehensive strategic cooperation between CSPC and AstraZeneca in the discovery of innovative peptide molecules and the development of long-acting delivery products [1] - CSPC will continue to advance its existing preclinical long-acting peptide pipeline while also discovering and developing other innovative long-acting peptide products for AstraZeneca [1]

Core Insights - AstraZeneca has announced a strategic partnership with CSPC Pharmaceutical Group, involving an upfront payment of $1.2 billion and a potential total deal value exceeding $18.5 billion [2][3] Group 1: Partnership Details - The collaboration focuses on developing innovative long-acting peptide drugs using CSPC's proprietary sustained-release drug delivery technology and AI drug discovery platform [2] - CSPC's long-acting technology allows for monthly or longer dosing intervals, enhancing patient compliance for long-term medication [2] - The partnership includes the overseas rights for a weight management product, SYH2082, which is a long-acting GLP-1R/GIPR agonist currently advancing to Phase I clinical trials, along with three preclinical projects targeting obesity and weight-related issues [2][3] Group 2: Financial Implications - CSPC will receive an upfront payment of $1.2 billion, with potential milestone payments of up to $3.5 billion for R&D and up to $13.8 billion for sales, plus a double-digit percentage royalty on net sales of the licensed products [3] - The global competition in GLP-1 development has intensified, with pharmaceutical companies focusing on next-generation weight loss therapies that improve patient experience and efficacy [3] Group 3: Previous Collaborations - This is not the first collaboration between AstraZeneca and CSPC; they previously established a partnership in June 2025 with a potential value exceeding $5 billion, focusing on AI-driven oral small molecule drug development for chronic and immune diseases [4] - AstraZeneca plans to invest over 100 billion RMB (approximately $15 billion) in China by 2030 to expand its presence in drug production and R&D [4]

Core Insights - AstraZeneca has announced a strategic partnership with CSPC Pharmaceutical Group, involving an upfront payment of $1.2 billion and a potential total deal value exceeding $18.5 billion [2][3] - The collaboration focuses on developing innovative long-acting peptide drugs utilizing CSPC's proprietary sustained-release drug delivery technology and AI-driven peptide drug discovery platform [2][3] - CSPC's technology allows for monthly or longer dosing intervals, enhancing patient compliance for long-term medication [2][3] Partnership Details - The agreement includes the overseas rights for a weight management product combination, featuring a clinical-ready project SYH2082 (a long-acting GLP1R/GIPR agonist) and three preclinical projects targeting obesity and weight-related issues [3] - CSPC stands to gain $12 billion in upfront payments, with potential milestone payments of up to $3.5 billion for R&D and up to $13.8 billion for sales, along with a double-digit percentage royalty on net sales [3] Industry Context - GLP-1 has emerged as a revolutionary target in the fields of diabetes and weight loss, with the global competition in GLP-1 research entering its "second half" [3] - Pharmaceutical companies are focusing on next-generation innovative weight loss therapies, including oral small molecules and ultra-long-acting formulations to improve patient experience and efficacy [3] - This is not the first collaboration between AstraZeneca and CSPC, as they previously established a partnership in June 2025 with a potential value exceeding $5 billion, focusing on AI-driven oral small molecule drug development for chronic and immune diseases [3] Investment Plans - AstraZeneca plans to invest over 100 billion RMB (approximately $15 billion) in China by 2030 to expand its presence in drug manufacturing and R&D [3]

Core Insights - AstraZeneca has entered into a strategic research and licensing agreement with CSPC Pharmaceutical Group, involving an upfront payment of $1.2 billion and a potential total deal value exceeding $18.5 billion [1][3]. Group 1: Partnership Details - The collaboration allows AstraZeneca to utilize CSPC's proprietary sustained-release drug delivery technology and AI drug discovery platform for developing innovative long-acting peptide drugs [1]. - CSPC's long-acting technology enables sustained release of peptide drugs, allowing for administration intervals of once a month or longer, enhancing patient compliance for long-term treatment [1][3]. - The partnership includes the overseas rights for a weight management product portfolio, including a clinical-ready project SYH2082 (long-acting GLP-1R/GIPR agonist) and three preclinical projects targeting obesity and weight-related issues [3]. Group 2: Financial Aspects - CSPC will receive an upfront payment of $1.2 billion, with potential milestone payments of up to $3.5 billion for research and up to $13.8 billion for sales, along with a double-digit percentage royalty based on annual net sales of the licensed products [3]. - AstraZeneca plans to invest over 100 billion RMB (approximately $15 billion) in China by 2030 to expand its pharmaceutical production and R&D footprint [4]. Group 3: Industry Context - GLP-1 has emerged as a revolutionary target in the diabetes and weight loss sectors, with the global GLP-1 development race entering its "second half," focusing on next-generation innovative weight loss therapies [3]. - The collaboration is not the first between CSPC and AstraZeneca, as they previously established a strategic partnership in June 2025, with a potential value exceeding $5 billion, focusing on AI-driven oral small molecule drug development for chronic and immune diseases [3].

【导读】贵金属概念股集体调整，农业板块快速走高 1月30日开盘，A股三大指数震荡走低，截至发稿，沪指跌0.51%，深成指跌0.80%，创业板指跌0.11%。 | 上证指数 | 深证成指 | 科创综指 | | | --- | --- | --- | --- | | 4136.78 | 14185.16 | 1828.84 | | | -21.21 -0.51% -114.92 -0.80% -2.26 -0.12% | | | | | 万得全A | 创业板指 | 北证50 | | | 6798.52 | 3300.89 | 1519.85 | | | -48.76 -0.71% -3.62 -0.11% | | -16.15 -1.05% | | | 沪深300 | 中证500 | 中证A500 | | | 4716.59 | 8407.95 | 5909.75 | | | -37.28 -0.78% -109.89 -1.29% -59.16 -0.99% | | | | | 中证1000 | 深证100 | 中证红利 | | | 8269.84 | 5823.30 | 5745.32 | | | -62.3 ...

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has fallen over 10%, currently down 9.07% at HKD 9.72, with a trading volume of HKD 25.63 billion [1] Group 1: Strategic Partnership - CSPC Pharmaceutical Group announced a strategic cooperation and licensing agreement with AstraZeneca for the development of innovative long-acting peptide drugs [1] - The collaboration includes a clinical-ready long-acting GLP-1/GIP dual-target agonist project SYH2082 and three preclinical projects, with plans to explore four additional new projects [1] Group 2: Financial Implications - The licensing agreement sets a new record for overseas business development transactions in the GLP-1 sector [1] - CSPC will receive an upfront payment of USD 1.2 billion, with potential milestone payments for research reaching up to USD 3.5 billion and sales milestone payments up to USD 13.8 billion [1] - Additionally, CSPC is entitled to a sales commission based on the annual net sales of related products, with the total potential transaction amounting to USD 18.5 billion [1]